D.E. Shaw & Co
GALT icon

D.E. Shaw & Co’s Galectin Therapeutics GALT Stock Holding History

D.E. Shaw & Co’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,607
Closed -$66K – 5045
2021
Q2 		$66K Sell
20,607
-25,168
-55% -$89.6K ﹤0.01% 4604
2021
Q1 		$99K Sell
45,775
-5,549
-11% -$12.4K ﹤0.01% 3932
2020
Q4 		$115K Buy
+51,324
New +$135K ﹤0.01% 3803
2020
Q3 		– Sell
-78,823
Closed -$241K – 3949
2020
Q2 		$241K Buy
+78,823
New +$198K ﹤0.01% 3714
2020
Q1 		– Sell
-19,092
Closed -$55K – 4041
2019
Q4 		$55K Buy
19,092
+6,165
+48% +$21.4K ﹤0.01% 3899
2019
Q3 		$47K Sell
12,927
-6,571
-34% -$23.8K ﹤0.01% 3729
2019
Q2 		$81K Buy
19,498
+3,148
+19% +$13.6K ﹤0.01% 3564
2019
Q1 		$84K Buy
+16,350
New +$78.5K ﹤0.01% 3491
2015
Q3 		– Sell
-140,753
Closed -$384K – 3772
2015
Q2 		$384K Sell
140,753
-1,117
-0.8% -$3.37K ﹤0.01% 3301
2015
Q1 		$475K Buy
141,870
+66,688
+89% +$238K ﹤0.01% 3077
2014
Q4 		$261K Buy
+75,182
New +$332K ﹤0.01% 3708
2014
Q3 		– Sell
-33,045
Closed -$456K – 4187
2014
Q2 		$456K Buy
+33,045
New +$411K ﹤0.01% 3607

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

D.E. Shaw & Co's GALT Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Galectin Therapeutics (GALT) in Q3 2021, closing a stake of 20,607 shares — an estimated $66K sold.

D.E. Shaw & Co first reported a position in GALT in Q2 2014 and held it in 12 quarters. The position peaked at $475K in Q1 2015. 70 funds tracked by Wall St. Rank hold GALT as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Galectin Therapeutics position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 20,607 Galectin Therapeutics shares in Q3 2021, an estimated $66K.
  • D.E. Shaw & Co first reported a position in Galectin Therapeutics in Q2 2014 and held it in 12 quarters.
  • D.E. Shaw & Co's Galectin Therapeutics position peaked at $475K in Q1 2015.
  • 70 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.